Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BX04
|
| gptkbp:brand |
gptkb:exenatide
|
| gptkbp:contraindication |
type 1 diabetes
severe renal impairment |
| gptkbp:discoveredBy |
gptkb:Amylin_Pharmaceuticals
|
| gptkbp:drugClass |
GLP-1 receptor agonist
|
| gptkbp:form |
solution for injection
prefilled pen |
| gptkbp:frequency |
twice daily
|
| gptkbp:halfLife |
2.4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Byetta
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
slows gastric emptying
increases insulin secretion suppresses glucagon secretion |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
injection
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
nausea vomiting diarrhea |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:Amylin_Pharmaceuticals
gptkb:exenatide gptkb:GLP-1_agonists |
| gptkbp:bfsLayer |
7
|